Evidence map›Paper›PMID 40754985›Full record

ArticleACS applied materials & interfaces2025

Positron Emission Tomography-Based Pharmacokinetics of mRNA-Lipid Nanoparticles: A Study Quantifying the ApoE and Macrophage Contribution.

Kohta Mohri, Takayuki Miyazaki, Shota Warashina, Maiko Takahashi, Qin Ren, Riho Iida, Yasuhiro Wada, Kazuya Maeda, Yasuyoshi Watanabe, Yuta Suzuki and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kohta MohriLaboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, 6-7-3 minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
Takayuki MiyazakiTsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
Shota WarashinaLaboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, 6-7-3 minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
Maiko TakahashiLaboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, 6-7-3 minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
Qin RenLaboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, 6-7-3 minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
Riho IidaDepartment of Pharmaceutical Informatics, Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8588, Japan.
Yasuhiro WadaLaboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, 6-7-3 minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
Kazuya MaedaLaboratory of Pharmaceutics, Kitasato University School of Pharmacy, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.ORCID 0000-0002-9174-5213
Yasuyoshi WatanabeLaboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, 6-7-3 minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
Yuta SuzukiTsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.ORCID 0000-0001-6240-8552
Hidefumi MukaiLaboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, 6-7-3 minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.ORCID 0000-0002-0749-8783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is important to clarify the pharmacokinetics of mRNA-loaded lipid nanoparticles (mRNA-LNPs), which have attracted attention as new pharmaceutical modalities for vaccines and therapeutic agents against various diseases. Positron emission tomography (PET) is expected to provide data to ensure the pharmacokinetics of mRNA-LNPs early after administration in detail, especially because of its high temporal resolution. In this study, we have developed a method for the preparation of

Indexed as

Apolipoproteins ELipidsMacrophagesNanoparticlesPositron-Emission TomographyRNA, MessengerAnimalsCopper RadioisotopesLiposomesLiverMaleMiceMice, Inbred C57BLTissue DistributionApolipoproteins ECopper RadioisotopesLipid NanoparticlesLipidsLiposomesRNA, Messenger64CuApoEintegration plot analysislipid nanoparticlesmRNApharmacokineticspositron emission tomography

Identifiers

PMID40754985
PMCPMC12356191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.